Changes in bone mineral density and trabecular bone score in Graves’ disease patients after anti-thyroid therapy

다국어 초록 (Multilingual Abstract)

Objective: The purpose of this study was to evaluate changes in bone quantity based on bone mineral density (BMD) and bone quality based on trabecular bone score (TBS) in Graves' disease patients after anti-thyroid therapy.
Research design and method: This retrospective study included premenopausal female and male patients with Graves' disease who received BMD measurement more than two times during treatment. BMD and thyroid function tests with free thyroxine (FT4), total triiodothyronine (T3), thyroid stimulating hormone (TSH), and TSH receptor antibody (TRAb) levels were collected two times during follow-up. TBS was calculated using TBS insight® software (version 2.1) from dual-energy X-ray absorptiometry images.
Results: Thirty Graves' disease patients (17 males, 56%; 13 premenopausal females, 44%) with a mean age of 35.3 ± 9.9 years were included.
The mean follow-up period was 20.7 ± 8.5 months. The median levels of FT4, TSH and TRAb improved at follow-up [2.55 ng/dL (Interquartile range (IQR) 2.07e3.78) to 1.28 ng/dL (IQR 1.23e1.39), 0.015 mIU/L (IQR 0.01e0.04) to 0.89 mIU/L (IQR 0.35e1.55), 17.0 IU/L (IQR 5.0e40.3) to 5.0 IU/L (5.0e6.0), respectively; p < 0.001]. Median BMD (lumbar spine) values also improved from 1.118 g/cm2 (IQR 1.000e1.119) to 1.167 g/cm2 (IQR 1.050e1.219) ( p ¼ 0.001) at follow-up. TBS increased from 1.377 (IQR 1.299e1.422) to 1.390 (IQR 1.327e1.430) after treatment ( p ¼ 0.038).
Conclusion: Both bone quality and density improved after anti-thyroid treatment in premenopausal female and male Graves' disease patients.

참고문헌 (Reference)

1 Romagnoli E, "“Trabecular Bone Score” (TBS): an indirect measure of bone micro-architecture in postmenopausal patients with primary hyperparathyroidism" 53 : 154-159, 2013

2 Boutroy S, "Trabecular bone score improves fracture risk prediction in non-osteoporotic women: the OFELY study" 24 : 77-85, 2013

3 Eriksen EF, "Trabecular bone remodeling and bone balance in hyperthyroidism" 6 : 421-428, 1985

4 Ballock RT, "Thyroxine is the serum factor that regulates morphogenesis of columnar cartilage from isolated chondrocytes in chemically defined medium" 126 : 1311-1318, 1994

5 Stevens DA, "Thyroid hormones regulate hypertrophic chondrocyte differentiation and expression of parathyroid hormone-related peptide and its receptor during endochondral bone formation" 15 : 2431-2442, 2000

6 Barnard JC, "Thyroid hormones regulate fibroblast growth factor receptor signaling during chondrogenesis" 146 : 5568-5580, 2005

7 Waung JA, "Thyroid hormone metabolism in skeletal development and adult bone maintenance" 23 : 155-162, 2012

8 Wang L, "Thyroid hormone interacts with the Wnt/beta-catenin signaling pathway in the terminal differentiation of growth plate chondrocytes" 22 : 1988-1995, 2007

9 Robson H, "Thyroid hormone acts directly on growth plate chondrocytes to promote hypertrophic differentiation and inhibit clonal expansion and cell proliferation" 141 : 3887-3897, 2000

10 Gogakos AI, "Thyroid and bone" 503 : 129-136, 2010

11 Murphy E, "The thyroid and the skeleton" 61 : 285-298, 2004

12 Bassett JH, "The molecular actions of thyroid hormone in bone" 14 : 356-364, 2003

13 Dentice M, "The Hedgehog-inducible ubiquitin ligase subunit WSB-1 modulates thyroid hormone activation and PTHrP secretion in the developing growth plate" 7 : 698-705, 2005

14 Novack DV, "TSH, the bone suppressing hormone" 115 : 129-130, 2003

15 Krolner B, "Spinal bone mineral content in myxoedema and thyrotoxicosis. Effects of thyroid hormone(s) and antithyroid treatment" 18 : 439-446, 1983

16 Bousson V, "Scientific Committee of the Groupe de Recherche et d'Information sur les O. Trabecular bone score (TBS): available knowledge, clinical relevance, and future prospects" 23 : 1489-1501, 2012

17 Lucidarme N, "Reduced bone mineral density at diagnosis and bone mineral recovery during treatment in children with Graves' disease" 137 : 56-62, 2000

18 Leslie WD, "Manitoba bone density P. TBS (trabecular bone score) and diabetes-related fracture risk" 98 : 602-609, 2013

19 Rosen CJ, "Longitudinal changes in lumbar bone density among thyrotoxic patients after attainment of euthyroidism" 75 : 1531-1534, 1992

20 Vestergaard P, "Hyperthyroidism, bone mineral, and fracture riskea meta-analysis" 13 : 585-593, 2003

21 Gomez Acotto C, "Hyperthyroidism influences ultrasound bone measurement on the Os calcis" 8 : 455-459, 1998

22 Gregory A, "Graves' disease" 358 : 2594-2605, 2008

23 Pothuaud L, "Evaluation of the potential use of trabecular bone score to complement bone mineral density in the diagnosis of osteoporosis: a preliminary spine BMD-matched, case-control study" 12 : 170-176, 2009

24 Toh SH, "Effect of hyperthyroidism and its treatment on bone mineral content" 145 : 883-886, 1985

25 Hans D, "Correlations between trabecular bone score, measured using anteroposterior dual-energy X-ray absorptiometry acquisition, and 3-dimensional parameters of bone microarchitecture: an experimental study on human cadaver vertebrae" 14 : 302-312, 2011

26 O'Shea PJ, "Contrasting skeletal phenotypes in mice with an identical mutation targeted to thyroid hormone receptor alpha1 or beta" 19 : 3045-3059, 2005

27 Seeman E, "Bone qualityethe material and structural basis of bone strength and fragility" 354 : 2250-2261, 2006

28 Jodar E, "Bone mineral density in male patients with L-thyroxine suppressive therapy and Graves disease" 69 : 84-87, 2001

29 Karga H, "Bone mineral density in hyperthyroidism" 61 : 466-472, 2004

30 Langdahl BL, "Bone mass, bone turnover, body composition, and calcium homeostasis in former hyperthyroid patients treated by combined medical therapy" 6 : 161-168, 1996

31 Bianco AC, "Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases" 23 : 38-89, 2002

32 Nagasaka S, "Antithyroid therapy improves bony manifestations and bone metabolic markers in patients with Graves' thyrotoxicosis" 47 : 215-221, 1997